Jiha Lee JihaRheum
1 week 1 day ago
In #PsA, obesity isn't just a comorbidity, it's a disease modifier. Pooled SPIRIT trials (n=1284): 43% had obesity. BMI≥30 vs normal: joint counts ↑, function ↓, fatigue ↑, CVD 55% vs 18%, HTN 52% vs 11%, DM 19% vs 3%. @RheumNow #EULAR2026 POS0460
Janet Pope Janetbirdope
1 week 1 day ago
Does #Rx w #immunesuppression w
#antifibrotic
Help #SARD-ILD?
YES.
N=40 SARD-ILD, 1/2 w UIP pattern
Use of #IS w #antifibrotic pt group had better survival
Small N and ?channeling bias
But interesting results
TAke home : Use IS + antifibrotic
#EULAR2026 #POS0530
@RheumNow https://t.co/tfxVVw27jJ
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 POS0044 TO ASPIRIN OR NOT in asymptomatic antiphospholipid antibodies (aPL) carriers? A study in Spain reported 4.6% VTE & 4.1% ATE.
-Aspirin reduced thrombosis without increasing bleeding risk in asymptomatic aPL inc. those <3 lab points (isolated LA) @RheumNow https://t.co/NyVjAfjAKd
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 POS0440 1-Year Open Label Extension Study of 6-monthly Inebilizumab, a CD19 depleter in #IgG4 disease:
-No flare in INEB group; 6% flare in PBO-INEB
-10.9% serious infections
-1 pt discontinued due to low IgG
Interested to see longer-term safety data @RheumNow https://t.co/PPUw81T8DZ
sheila RHEUMarampa
1 week 1 day ago
Prof. Pedro Machado shares this important slide on a quick guide to #vaccination in patients w/ RMDs highlighting which vaccines are universally indicated, accdg to epidemiologic risk and w/ CIs.
#EULAR2026 @RheumNow https://t.co/JmTSC1uaph
sheila RHEUMarampa
1 week 1 day ago
#Vaccination in Rheum
📍Hold MTX 1-2wks post vax
📍For Bcell depleters, timing is based on B-cell repop’n kinetics, not fixed calendar intervals.
THM: Assess vax need at dx, vax w/o delay
#EULAR2026 @RheumNow https://t.co/6ptl8gyBLR
A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional
